Questo sito o gli strumenti terzi da questo utilizzati si avvalgono di cookie necessari al funzionamento ed utili alle finalità illustrate nella cookie policy. Se vuoi saperne di più o negare il consenso a tutti o ad alcuni cookie, consulta la  Cookie Policy.

ATTIVO

Objectives and Endpoints

Study MX39795 will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in patients with cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control (CR, PR or SD) after 3 cycles of first-line platinum doublet induction chemotherapy. Molecularly-guided therapies will include 7 targeted cancer therapy regimens and 2 cancer immunotherapy regimens, and will be chosen based on each patient’s comprehensive genomic profile (see below for further details). Specific objectives and corresponding endpoints for the study are outlined in Synopsis Table 1, where “molecularly-guided therapy” refers to a pooled treatment group comprising patients who received a targeted agent or cancer immunotherapy. 

STRUTTURA DI RIFERIMENTO

Ospedale S.Maria della Misericordia - Centro Operativo Studi Clinici S.C.Oncologia Medica

 

SCARICA DOCUMENTO DI SINOSSI

PER INFORMAZIONI CONTATTARE IL + 39 0755784107 O SCRIVERE  reteoncol.umbria@ospedale.perugia.it